Basic Information

Gene symbol GRB2 Synonyms ASH, EGFRBP-GRB2, Grb3-3, MST084, MSTP084, NCKAP2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description growth factor receptor bound protein 2

GTO ID GTC1359
Trial ID NCT01159028
Disease Leukemia | Myelodysplastic Syndrome
Altered gene GRB2
Therapeutic/Target gene Target gene
TherapyASO
Treatment BP1001|Liposomal Grb2 Antisense Oligonucleotide|Liposomal Grb-2|L-Grb-2
PhasePhase1
Recruitment statusCompleted
TitleA Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Year2010
CountryUnited States
Company sponsorBio-Path Holdings, Inc.
Other ID(s)2003-0578 (v) 08-8
Vector information
Vectorliposome

Clinical Result

Cohort1: BP1001_dose level 1
Administration route intravenous injection
Dosage BP1001, 5 mg/m^2, twice weekly, for 28 days
Pts 13
Age Adult, Older_Adult
References PMID: 29550383
Cohort2: BP1001_dose level 2
Administration route intravenous injection
Dosage BP1001, 10 mgm^2, twice weekly, for 28 days
Pts 6
Age Adult, Older_Adult
References PMID: 29550383
Cohort3: BP1001_dose level 3
Administration route intravenous injection
Dosage BP1001, 20 mg/m^2, twice weekly, for 28 days
Pts 3
Age Adult, Older_Adult
References PMID: 29550383
Cohort4: BP1001_dose level 4
Administration route intravenous injection
Dosage BP1001, 40 mg/m^2, twice weekly, for 28 days
Pts 3
Age Adult, Older_Adult
References PMID: 29550383
Cohort5: BP1001_dose level 5
Administration route intravenous injection
Dosage BP1001, 60 mg/m^2, twice weekly, for 28 days
Pts 3
Age Adult, Older_Adult
References PMID: 29550383
Cohort6: BP1001_dose level 6
Administration route intravenous injection
Dosage BP1001, 90 mg/m^2, twice weekly, for 28 days
Pts 4
Age Adult, Older_Adult
References PMID: 29550383
Cohort7: BP1001_dose level 5_cytarabine
Administration route intravenous injection|subcutaneous injection
Dosage BP1001, 60 mg/m^2, twice daily, 10 consecutive days|cytarabine, 20 mg, twice daily, 10 consecutive days
Pts 4
Age Adult, Older_Adult
References PMID: 29550383
Cohort8: BP1001_dose level 6_cytarabine
Administration route intravenous injection|subcutaneous injection
Dosage BP1001, 60 mg/m^2, twice daily, 10 consecutive days|cytarabine, 20 mg, twice daily, 10 consecutive days
Pts 3
Age Adult, Older_Adult
References PMID: 29550383

Relationship Graph

Overview of Knowledge Graph